Decision tree-based modeling of androgen pathway genes and prostate cancer risk
- PMID: 21493872
- PMCID: PMC3111844
- DOI: 10.1158/1055-9965.EPI-10-0996
Decision tree-based modeling of androgen pathway genes and prostate cancer risk
Abstract
Background: Inherited variability in genes that influence androgen metabolism has been associated with risk of prostate cancer. The objective of this analysis was to evaluate interactions for prostate cancer risk by using classification and regression tree (CART) models (i.e., decision trees), and to evaluate whether these interactive effects add information about prostate cancer risk prediction beyond that of "traditional" risk factors.
Methods: We compared CART models with traditional logistic regression (LR) models for associations of factors with prostate cancer risk using 1,084 prostate cancer cases and 941 controls. All analyses were stratified by race. We used unconditional LR to complement and compare with the race-stratified CART results using the area under curve (AUC) for the receiver operating characteristic curves.
Results: The CART modeling of prostate cancer risk showed different interaction profiles by race. For European Americans, interactions among CYP3A43 genotype, history of benign prostate hypertrophy, family history of prostate cancer, and age at consent revealed a distinct hierarchy of gene-environment and gene-gene interactions, whereas for African Americans, interactions among family history of prostate cancer, individual proportion of European ancestry, number of GGC androgen receptor repeats, and CYP3A4/CYP3A5 haplotype revealed distinct interaction effects from those found in European Americans. For European Americans, the CART model had the highest AUC whereas for African Americans, the LR model with the CART discovered factors had the largest AUC.
Conclusion and impact: These results provide new insight into underlying prostate cancer biology for European Americans and African Americans.
©2011 AACR.
Figures




Similar articles
-
Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.Asian J Androl. 2015 Mar-Apr;17(2):285-91. doi: 10.4103/1008-682X.133320. Asian J Androl. 2015. PMID: 25337833 Free PMC article.
-
CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer.Cancer Res. 2004 Nov 15;64(22):8461-7. doi: 10.1158/0008-5472.CAN-04-1651. Cancer Res. 2004. PMID: 15548719
-
CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians.Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1257-61. doi: 10.1158/1055-9965.EPI-04-0534. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 15894682
-
Genetic polymorphisms and prostate cancer risk.World J Urol. 2004 Feb;21(6):414-23. doi: 10.1007/s00345-003-0378-4. Epub 2003 Nov 26. World J Urol. 2004. PMID: 14648103 Review.
-
Genetic contribution to variable human CYP3A-mediated metabolism.Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94. doi: 10.1016/s0169-409x(02)00066-2. Adv Drug Deliv Rev. 2002. PMID: 12406645 Review.
Cited by
-
Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.Am J Cancer Res. 2013 Apr 3;3(2):127-51. Print 2013. Am J Cancer Res. 2013. PMID: 23593537 Free PMC article.
-
Genetic variation in CYP3A43 is associated with response to antipsychotic medication.J Neural Transm (Vienna). 2015 Jan;122(1):29-34. doi: 10.1007/s00702-014-1298-8. Epub 2014 Aug 24. J Neural Transm (Vienna). 2015. PMID: 25150845 Review.
-
Prognostic classification index in Iranian colorectal cancer patients: Survival tree analysis.South Asian J Cancer. 2016 Jan-Mar;5(1):23-6. doi: 10.4103/2278-330X.179703. South Asian J Cancer. 2016. PMID: 27169118 Free PMC article.
-
Human Orphan Cytochromes P450: An Update.Curr Drug Metab. 2022;23(12):942-963. doi: 10.2174/1389200224666221209153032. Curr Drug Metab. 2022. PMID: 36503398
-
Identification of functional modules by integration of multiple data sources using a Bayesian network classifier.Circ Cardiovasc Genet. 2014 Apr;7(2):206-17. doi: 10.1161/CIRCGENETICS.113.000087. Circ Cardiovasc Genet. 2014. PMID: 24736851 Free PMC article.
References
-
- Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–73. - PMC - PubMed
-
- ACS. Cancer Facts and Figures 2010. American Cancer Society, Inc; 2010.
-
- Zeigler-Johnson C, Friebel T, Walker AH, Wang Y, Spangler E, Panossian S, et al. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 2004;64:8461–7. - PubMed
-
- Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1998;90:1225–9. - PubMed
-
- Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:928–32. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical